title: Splenic marginal zone lymphoma: transformation to diffuse large B-cell lymphoma with isolated cerebral manifestation.
authors.affiliation: Department of Medicine, University Hospital of Muenster, Muenster, Germany.
authors.forename: Nils H
authors.initials: NH
authors.lastname: Thoennissen
authors.forename: Kathy
authors.initials: K
authors.lastname: Keyvani
authors.forename: Hans U
authors.initials: HU
authors.lastname: Voelker
authors.forename: Janbernd
authors.initials: J
authors.lastname: Bremer
authors.forename: Utz
authors.initials: U
authors.lastname: Krug
authors.forename: Carsten
authors.initials: C
authors.lastname: Müller-Tidow
authors.forename: Peter
authors.initials: P
authors.lastname: Koch
authors.forename: Hans K
authors.initials: HK
authors.lastname: Müller-Hermelink
authors.forename: Wolfgang E
authors.initials: WE
authors.lastname: Berdel
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D008223:Lymphoma / Q000473:pathology* / Q000628:therapy*; D016393:Lymphoma, B-Cell / Q000473:pathology* / Q000628:therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D000069283:Rituximab; D013160:Splenic Neoplasms / Q000473:pathology* / Q000628:therapy*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone